Somatostatin receptor-targeted anti-cancer therapy

Current Drug Delivery

Volumn 8, Issue 1, 2011, Pages 2-10

  Sun, Li Chun ^a   Coy, David H ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cancer therapy; Conjugates; Somatostatin; Somatostatin receptors

Indexed keywords

AN 51; ANTINEOPLASTIC AGENT; BIM 23A760; BIM 23A761; CAMPTOTHECIN; COLCHICINE; COMBRETASTATIN; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DOPAMINE; DOXORUBICIN; IRINOTECAN; JF 0769; JF 1081; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; OCTREOTIDE; PACLITAXEL; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TOPOTECAN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG BINDING; DRUG FORMULATION; DRUG RELEASE; DRUG SENSITIVITY; DRUG STABILITY; DRUG TARGETING; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 78650884323     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720111793663633     Document Type: Article

References (90)

1. Mezo, G.; Manea, M. Receptor-mediated tumor targeting based on peptide hormones, Expert Opin Drug Deliv., 2010, 7, 79-96.
2. Sun, L.-C.; Coy, D.H. Cytotoxic conjugates of peptide hormones for cancer chemotherapy. Drugs Future, 2008, 33, 217-223.
3. Reubi, J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev., 2003, 24, 389-427.
4. Fuselier, J.A.; Sun, L.-C.; Woltering, S.N.; Murphy, W.A.; Vasilevich, N.; Coy, D.H. An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg. Med.Chem. Lett., 2003, 13, 799-803.
5. Sun, L.-C.; Fuselier, J.A.; Murphy, W.A.; Coy, D.H. Antisense peptide nucleic acids conjugated to somatostatin analogs and targeted at the n-myc oncogene display enhanced cytotoxity to human neuroblastoma IMR32 cells expressing somatostatin receptors. Peptides, 2002, 23, 1557-1565.
6. Sun, L.-C., Luo, J.; Mackey, V.L.; Fuselier, J.A.; Coy, D.H. Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anticancer Drugs, 2007, 18, 341-348.
7. Nagy, A.; Schally, A.V. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a smarter chemotherapy. Curr. Pharm. Des., 2005, 11, 1167-1180.
8. Oyen, W.; Bodei, L.; Giammarile, F. Targeted therapy in nuclear medicine-current status and future prospects. Ann. Oncol., 2007, 18(11), 1782-92.
9. De Jong, M.; Valkema, R.; Jamar, F. Somatostatin receptor targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin. Nucl. Med., 2002, 32,133-140.
10. Mankoff, D.A; Link, J.M.; Linden, H.M.; Sundararajan, L; Krohn, K.A. Tumor receptor imaging. J. Nucl. Med., 2008 2, 149S-163S.
11. Bajusz, S.; Janaky, T.; Csernus, V.J.; Bokser, L.; Fekete, M.; Srkalovic, G.; Redding, T.W.; Schally, A.V. Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA, 1989, 86, 6313-6317.
12. Bajusz, S.; Janaky, T.; Csernus, V.J.; Bokser, L.; Fekete, M.; Srkalovic, G.; Redding, T.W.; Schally, A.V. Highly potent analogues of luteinizing hormone-releasing hormone containing Dphenylalanine nitrogen mustard in position 6. Proc. Natl. Acad. Sci. USA, 1989, 86, 6318-6322.
13. Safavy, A; Raisch, K.P.; Khazaeli, M.B.; Buchsbaum, D.J,; Bonner, J.A. Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes. J. Med. Chem., 1999, 42, 4919-4924.
14. Mier, W.; Eritja, R.; Mohammed, A.; Haberkorn, U.; Eisenhut, M. Preparation and evaluation of tumor-targeting peptideoligonucleotide conjugates. Bioconjug. Chem., 2000, 11, 855-860.
15. Schaer, J.C.; Waser, B.; Mengod, G.; Reubi, J.C. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int. J. Cancer, 1997, 70, 530-537.
16. O'Leary, J.; Muggia, F.M. Camptothecins: a review of their development and schedules of administration. Eur. J. Cancer, 1998, 34, 1500-1508.
17. Subramanian, D.; Muller, M.T. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan. Oncol Res., 1995, 7, 461-469.
18. Dodds, H.M.; Craik, D.J.; Rivory, L.P. Photodegradation of irinotecan (CPT-11) in aqueous solutions: identification of fluorescent products and influence of solution composition. J. Pharm. Sci., 1997, 86, 1410-1416.
19. Møller, L.N.; Stidsen, C.E.; Hartmann, B.; Holst, J.J. Somatostatin receptors. Biochim. Biophys. Acta., 2003, 1616, 1-84.
20. Reisine, T.; Bell, G.I. Molecular properties of somatostatin receptors. Neuroscience, 1995, 67, 777-790.
21. Watt, H L.; Kharmate, G.; Kumar, U. Biology of somatostatin in breast cancer. Mol Cell Endocrinol., 2008, 286, 251-261.
22. Epelbaum, J. Somatostatin in the central nervous system: physiology and pathological modifications. Prog. Neurobiol., 1986, 27, 63-100.
23. Raynor, K.; Reisine, T. Somatostatin receptors. Crit. Rev,Neurobiol., 1992, 6, 273-289.
24. Volante, M.; Rosas, R.; Allìa, E.; Granata, R.; Baragli, A.; Muccioli, G.; Papotti, M, Somatostatin, cortistatin and their receptors in tumours., Mol. Cell. Endocrinol., 2008, 286, 219-229.
25. Patel, Y.C. Somatostatin and its receptor family. Front Neuroendocrinol., 1999, 20, 157-198.
26. Susini, C.; Buscail, L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol., 2006, 17, 1733-1742.
27. Pyronnet, S.; Bousquet, C.; Najib, S.; Azar, R.; Laklai, H.; Susini, C. Antitumor effects of somatostatin., Mol.Cell.Endocrinol., 2008, 286, 230-237.
28. Coy, D.H.; Taylor, J.E. Receptor-specific somatostatin analogs: correlations with biological activity. Metabolism, 1996, 45, 21-23.
29. Reubi, J.C.; Schär, J.C.; Waser, B.; Wenger, S.; Heppeler, A.; Schmitt, J.S.; Mäcke, H.R. Affinity profiles for human somatostatin receptor subtypes sstr1-sstr5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med., 2000, 27, 273-282.
30. Weckbecker, G.; Raulf, F.; Stolz, B.; Bruns, C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol. Ther., 1993, 60, 245-264.
31. Shimon, I.; Taylor, J.E.; Dong, J.Z.; Bitonte, R.A.; Kim, S.; Morgan, B.; Coy, D.H.; Culler M.D.; Melmed, S. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of sstr2 and sstr5 for growth hormone, thyroidstimulating hormone, and prolactin regulation. J. Clin. Invest., 1997, 99, 789-798.
32. Viguerie, N.; TahiriJouti, N.; Ayral, A.M.; Cambillau, C.; Scemama, J.L.; Bastié, M.J.; Knuhtsen, S.; Estève, J.P.; Pradayrol, L.; Susini, C. Direct inhibitory effects of a somatostatin analog, SMS 201-995, on AR4-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism. Endocrinology, 1989, 124, 1017-1025.
33. Karashima, T.; Schally, A.V. Inhibitory effects of somatostatin analogs on prolactin secretion in rats pretreated with estrogen or haloperidol. Proc. Soc. Exp. Biol. Med., 1987, 185, 69-75.
34. Bruns, C.; Lewis, I.; Briner, U.; Meno-Tetang, G.; Weckbecker, G SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile, Eur J Endocrinol., 2002, 146, 707-716.
35. Lesche, S.; Lehmann, D.; Nagel, F.; Schmid, H.A.; Schulz, S. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J. Clin. Endocrinol. Metab., 2009, 94, 654-661.
36. Schmid, H.A. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol., 2008, 286, 69-74.
37. D'Addona, D.; Carotenuto, A.; Novellino, E.; Piccand, V.; Reubi, J.C.; Di Cianni, A.; Gori, F.; Papini, A.M.; Ginanneschi, M. Novel sst5-selective somatostatin dicarba-analogues: synthesis and conformation-affinity relationships. J. Med. Chem., 2008, 51, 512-520.
38. Saveanu, A.; Gunz, G.; Dufour, H.; Caron, P.; Fina, F.; Ouafik, L.; Culler, M.D.; Moreau, J.P.; Enjalbert, A.; Jaquet, P. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J. Clin. Endocrinol. Metab., 2001, 86, 140-145.
39. Liapakis, G.; Hoeger, C.; Rivier, J.; Reisine, T. Development of a selective agonist at the somatostatin receptor subtype sstr1. J. Pharmacol. Exp. Ther., 1996, 276, 1089-1094.
40. Yang, L.; Berk, S.C.; Rohrer, S.P.; Mosley, R.T.; Guo, L.; Underwood, D.J.; Arison, B.H.; Birzin, E.T.; Hayes, E.C.; Mitra, S.W.; Parmar, R.M.; Cheng, K.; Wu, T.J.; Butler, B.S.; Foor, F.; Pasternak, A.; Pan, Y.; Silva, M.; Freidinger, R.M.; Smith, R.G.; Chapman, K.; Schaeffer, J.M.; Patchett, A.A. Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc. Natl. Acad. Sci. USA., 1998, 95, 10836-10841.
41. Rohrer, S.P.; Birzin, E.T.; Mosley, R.T.; Berk, S.C.; Hutchins, S.M.; Shen, D.M.; Xiong, Y.; Hayes, E.C.; Parmar, R.M.; Foor, F.; Mitra, S.W.; Degrado, S.J.; Shu, M.; Klopp, J.M.; Cai, S.J.; Blake, A.; Chan, W.W.; Pasternak, A.; Yang, L.; Patchett, A.A.; Smith, R.G.; Chapman, K.T.; Schaeffer, J.M. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science, 1998, 282, 737-740.
42. Grozinsky-Glasberg, S.; Shimon, I.; Korbonits, M.; Grossman, A.B. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms, Endocr. RelatCancer, 2008, 15, 701-20.
43. Gustafsson, B.I.; Kidd, M.; Modlin, I.M. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr. Opin. Oncol., 2008, 20, 1-12
44. Borbath, I.; Leclercq, I.A.; Sempoux, C.; Abarca-Quinones, J.; Desaeger, C.; Horsmans, Y. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chem. Biol. Interact., 2010, 183, 238-248.
45. Van Essen, M.; Krenning, E.P.; Kam, B.L.; de Jong, M.; Valkema, R.; Kwekkeboom, D.J. Peptide receptor radionuclide therapy for endocrine tumors. Nat. Rev. Endocrinol., 2009, 5, 382-393.
46. Lewis, J.S.; Anderson, C.J. Radiometallabeled somatostatin analogs for applications in cancer imaging and therapy. Methods, Mol. Biol., 2007, 386, 227-240.
47. Nayak, T.K.; Norenberg, J.P.; Anderson, T.L.; Prossnitz, E.R.; Stabin, M.G.; Atcher, R.W. Somatostatin receptor-targeted alphaemitting 213Bi is therapeutically more effective than beta(-)- emitting 177Lu in human pancreatic adenocarcinoma cells, Nucl. Med tBiol., 2007, 34, 185-193.
48. Basu, S.; Kumar, R.; Rubello, D.; Fanti, S.; Alavi, A. PET imaging in neuroendocrine tumors: current status and future prospects, Minerva. Endocrinol., 2008, 33, 257-275.
49. Sun, L.; Fuselier, J.A.; Coy, D.H. Effects of camptothecin conjugated to a somatostatin analog vector on growth of tumor cell lines in culture and related tumors in rodents. Drug Deliv., 2004, 11, 231-238.
50. Shen, H.; Hu, D.; Du, J.; Wang, X.; Liu, Y.; Wang, Y.; Wei, J.M.; Ma, D.; Wang, P.; Li, L. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice. Eur. J. Pharmacol., 2008, 601, 23-29.
51. Patel, Y.C.; Srikant, C.B. Somatostatin receptors, Trends Endocrinol Metab., 1997, 8, 398-405.
52. Taylor, J.E.; Theveniau, M.A.; Bashirzadeh, R.; Reisine, T.; Eden, P.A. Detection of somatostatin receptor subtype 2 (sstr2) in established tumors and tumor cell lines: evidence for sstr2 heterogeneity. Peptides, 1994, 15, 1229-1236.
53. Denzler, B.; Reubi, J.C. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer, 1999, 85, 188-198.
54. Righi, L.; Volante, M.; Tavaglione, V.; Billè, A.; Daniele, L.; Angusti, T.; Inzani, F.; Pelosi, G.; Rindi, G.; Papotti, M. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann. Oncol., 2009, 21(3), 548-555.
55. Ioannou, M.; Papagelopoulos, P.J.; Papanastassiou, I.; Iakovidou, I.; Kottakis, S.; Demertzis, N, Detection of somatostatin receptors in human, osteosarcoma. World J. Surg. Oncol., 2008, 6, 99.
56. Eden, P.A.; Taylor, J.E. Somatostatin receptor subtype gene expression in human and rodent tumors. Life Sci., 1993, 53, 85-90.
57. Klagge, A.; Krause, K.; Schierle, K., Steinert, F.; Dralle, H.; Fuhrer, D. Somatostatin receptor subtype expression in human thyroid tumours., Horm. Metab. Res., 2010, 42(4), 237-240.
58. Fujita, T.; Yamaji, Y.; Sato, M.; Murao, K.; Takahara, J. Gene expression of somatostatin receptor subtypes, sstr1 and sstr2, in human lung cancer cell lines. Life Sci., 1994, 55, 1797-1806
59. Reubi, J.C.; Waser, B.; Liu, Q.; Laissue, J.A.; Schonbrunn, A. Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: membranous versus intracellular location. J. Clin. Endocrinol. Metab., 2000, 85, 3882-3891.
60. Schulz, S.; Schmitt, J.; Weise, W. Frequent expression of immunoreactive somatostatin receptors in cervical and endometrial cancer. Gynecol Oncol., 2003, 89, 385-390.
61. Reubi, J.C.; Waser, B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 781-793.
62. Reubi, J.C.; Laissue, J.; Krenning, E.; Lamberts, S.W. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J. Steroid. Biochem. Mol. Biol., 1992, 43, 27-35.
63. Reubi, J.C.; Krenning, E.; Lamberts, S.W.; Kvols, L. In vitro detection of somatostatin receptors in human tumors. Metabolism, 1992, 41, 104-110.
64. Reubi, J.C.; Schaer, J.C.; Laissue, J.A.; Waser, B. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism, 1996, 45, 39-41.
65. Woltering, E.A. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer, Biother. Radiopharm., 2003, 1, 601-9.
66. Reubi, J.C.; Mazzucchelli, L.; Hennig, I.; Laissue, J.A. Local up- regulation of neuropeptide receptors in host blood vessels around human colorectal cancers. Gastroenterology, 1996, 110, 1719-1726.
67. Gulec, S.A.; Drouant, G.J.; Fuselier, J.; Anthony, C.T.; Heneghan, J.; DelCarpio, J.B.; Coy, D.H.; Murphy, W.A.; Woltering, E.A., Antitumor and antiangiogenic effects of somatostatin receptor-targeted in situ radiation with (111) In-DTPA-JIC 2DL. J. Surg. Res. 2001, 97, 131-137.
68. Watson, J.C.; Balster, D.A.; Gebhardt, B.M.; O'Dorisio, TM.; O'Dorisio, M.S.; Espenan G.D.; Drouant, G.J.; Woltering, E.A. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br. J. Cancer, 2001, 85, 266-272.
69. Roosterman, D.; Roth, A.; Kreienkamp, H.J.; Richter, D.; Meyerhof, W. Distinct agonist-mediated endocytosis of cloned rat somatostatin receptor subtypes expressed in insulinoma cells. J. Neuroendocrinol., 1997, 9, 741-751.
70. Schally, A.V. New approaches to the therapy of various tumors based on peptide analogues. Horm. Metab. Res., 2008, 40, 315-322.
71. O'Leary, J.J.; Shapiro, R.L.; Ren, C.J.; Chuang, N.; Cohen, H.W.; Potmesil, M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin. Cancer, Res., 1999, 5, 181-187.
72. Clements, M.K.; Jones, C.B.; Cumming, M.; Daoud, S.S. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother. Pharmacol., 1999, 44, 411-416.
73. Slichenmyer, W.J.; Rowinsky, E.K.; Donehower, R.C.; Kaufmann, S.H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 1993, 85, 271-291.
74. Sun, L.; Mackey, L.V.; Luo, J.; Fuselier, J.A.; Coy, D.H, Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice, Clin Med Oncol., 2008, 2, 491-499
75. Bezerra, Y.; Fuselier, J.A.; Peyman, GA.; Oner, H.; Drouant, G.; Coy, D.H. Study of inhibitory effects of an antiangiogenic somatostatin-camptothecin. conjugate on laserinduced choroidal neovascularization in rats. Retina, 2005, 25, 345-354.
76. Sun, LC.; Luo, J.; Mackey, L.V.; Fuselier, J.A.; Coy, D.H. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer, Lett., 2007, 246, 157-166.
77. Huang, C.M.; Wu, Y.T.; Chen, S.T. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. Chem. Biol., 2000, 7, 453-461.
78. Nagy, A.; Schally, A.V.; Halmos, G.; Armatis, P.; Cai, R.Z.; Csernus, V.; Kovács, M.; Koppán, M.; Szepeshàzi, K.; Kahán, Z, Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative,2- pyrrolinodoxorubicin, Proc. Natl. Acad. Sci. USA, 1998, 95, 1794-1799.
79. Engel, J.B.; Schally, A.V.; Dietl, J.; Rieger, L.; Hönig, A. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm., 2007, 4, 652-658.
80. Schally, A.V.; Nagy, A. Chemotherapy targeted to cancers through tumoral hormone receptors, Trends Endocrinol Metab., 2004, 15, 300-310.
81. Schally, A.V.; Nagy, A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol., 1999, 141, 1-14.
82. Kiaris, H.; Schally, A.V.; Nagy, A.; Szepeshazi, K.; Hebert, F.; Halmos, G, A targeted cytotoxic somatostatin (sst) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (sclc) and H-157 non-sclc in nude mice, Eur. J. Cancer, 2001, 37, 620-628.
83. Engel J.B.; Schally, A.V.; Halmos, G.; Baker, B.; Nagy, A.; Keller, G., Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins, Endocr Relat. Cancer, 2005, 12, 999-1009.
84. Radulovic, S.; Nagy, A.; Szoke, B.; Schally, A.V. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Lett., 1992, 62, 263-271.
85. Ren, S.G.; Kim, S.; Taylor, J.; Dong, J.; Moreau, J.P.; Culler, M.D.; Melmed, S. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J. Clin. Endocrinol. Metab., 2003, 88, 5414-5421.
86. Jaquet, P.; Gunz, G.; Saveanu, A.; Dufour, H.; Taylor, J.; Dong, J.; Kim, S.; Moreau, J.P.; Enjalbert, A.; Culler, M.D. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur. J. Endocrinol., 2005, 153, 135-141.
87. Gruszka, A.; Ren, S.G.; Dong, J.; Culler, M.D.; Melmed, S. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology, 2007, 148, 6107-6114.
88. Jaquet, P.; Gunz, G.; Saveanu, A.; Barlier, A.; Dufour, H.; Taylor, J.; Dong, J.; Kim, S.; Moreau, J.P.; Culler, M.D. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J. Endocrinol. Invest., 2005, 28, 21-27.
89. Peverelli, E.; Olgiati, L.; Locatelli, M.; Magni, P.; Fustini, M.F.; Frank, G.; Mantovani, G.; Beck-Peccoz, P.; Spada, A.; Lania, A. The dopamine-somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways. Cancer Lett., 2009, 288(2), 170-176.
90. Kidd, M.; Drozdov, I.; Joseph, R.; Pfragner, R.; Culler, M.; Modlin, I. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer, 2008, 113, 690-700.